April is also in Q2 of 2021, let's not discredit that.
It is also of note that this provides some much needed clarification on the 'Q' referencing from the previous MD&A and prospectus confusion. What is favorable here is the company has estimated that interim results should be complete in the next few weeks (mistake that there are two line-items with the same interim results suggestion? - Maybe a 210 and a 400 interim?)
With regard to your herd immunity suggestion, frankly, it's absurd given every PR release by international and national organizations (and the Fauci himself) saying even 2022 will have problems. There will be treatments needed, and the provisional patent filing covers bucillamine as a treatment for 'infectious diseases', not just COVID itself. I think buc still has a long way to go even outside the COVID space.